The meeting, attended by Egypt’s commercial office, focused on Cairo's strategic goal to transform into a regional hub for pharmaceutical production.
Ambassador El-Etreby emphasized that developing the
pharmaceutical sector is a national priority, aligning with the expansion of
Egypt’s Universal Health Insurance system, a project already receiving
significant support from Japan.
He highlighted recent economic reforms that have improved
Egypt's business climate, specifically pointing to the Suez Canal Economic Zone
(SCZONE). "The dedicated pharmaceutical zone within SCZONE offers a strategic
base for companies to manufacture medicines and medical equipment for export to
Middle Eastern, European, and African markets," El-Etreby said.
Seiji Ohara detailed the Japanese firm’s specialized
operations, which focus on the manufacture of treatments for rare diseases, generic
medicines, and Active Pharmaceutical Ingredients (APIs)produced across three major
plants in Shiga Prefecture.
Ohara also showcased the company's research and development
efforts in creating new treatments for cancer, liver diseases, and neurological
disorders.
Both parties agreed to maintain a steady exchange of information to explore specific investment opportunities and joint ventures.